Spots Global Cancer Trial Database for lanreotide
Every month we try and update this database with for lanreotide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors | NCT05048901 | Neuroendocrine ... | Cabozantinib Lanreotide | 20 Years - | National Health Research Institutes, Taiwan | |
| Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors | NCT05048901 | Neuroendocrine ... | Cabozantinib Lanreotide | 20 Years - | National Health Research Institutes, Taiwan | |
| Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET | NCT03083210 | Neuroendocrine ... | Lanreotide | 18 Years - | Samsung Medical Center | |
| Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues | NCT02351128 | Carcinoma, Merk... | Lanreotide | 18 Years - | University Hospital, Grenoble | |
| A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide | NCT03289741 | Neuroendocrine ... | Octreotide LAR Lanreotide Questionnaires | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors | NCT01731925 | Carcinoid Tumor... | Lanreotide Placebo (for su... Sunitinib | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors | NCT03043664 | Gastroenteropan... | Lanreotide Pembrolizumab | 18 Years - | Duke University | |
| A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. | NCT01861717 | Acromegaly | lanreotide | 18 Years - 75 Years | Saint John's Cancer Institute | |
| Circulating Tumor Cells and Tumor DNA in HCC and NET | NCT02973204 | Carcinoma, Hepa... Neuroendocrine ... | Sorafenib Radiofrequency ... Everolimus Lanreotide | 18 Years - | University of Aarhus | |
| Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly | NCT00627796 | Acromegaly | Lanreotide-Auto... | 18 Years - 80 Years | Federico II University | |
| Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres | NCT02859064 | Neuroendocrine ... Gastrointestina... Carcinoid Tumor... | Lanreotide Y-90 microspher... | 18 Years - | SCRI Development Innovations, LLC | |
| An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome | NCT00774930 | Carcinoid Syndr... | Lanreotide Placebo | 18 Years - | Ipsen | |
| GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma | NCT00495846 | Advanced Hepato... | Octreotide-LAR,... Locoregional tr... | 18 Years - 75 Years | Federico II University | |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | NCT05477576 | GEP-NET Gastroenteropan... Gastroenteropan... Neuroendocrine ... Carcinoid Carcinoid Tumor Pancreatic NET | RYZ101 Everolimus 10 m... Sunitinib 37.5 ... Octreotide LAR ... Lanreotide 120M... | 18 Years - | RayzeBio, Inc. | |
| Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour | NCT00842348 | Non Functioning... | lanreotide (Aut... | 18 Years - | Ipsen | |
| Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors | NCT05048901 | Neuroendocrine ... | Cabozantinib Lanreotide | 20 Years - | National Health Research Institutes, Taiwan | |
| Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly | NCT00627796 | Acromegaly | Lanreotide-Auto... | 18 Years - 80 Years | Federico II University | |
| Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres | NCT02859064 | Neuroendocrine ... Gastrointestina... Carcinoid Tumor... | Lanreotide Y-90 microspher... | 18 Years - | SCRI Development Innovations, LLC | |
| Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET | NCT03083210 | Neuroendocrine ... | Lanreotide | 18 Years - | Samsung Medical Center | |
| Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome | NCT04065165 | Small Intestina... Carcinoid Heart... | Telotristat Eth... Lanreotide | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) | NCT03946527 | Paraganglioma Pheochromocytom... | Lanreotide | 18 Years - | Columbia University | |
| Circulating Tumor Cells and Tumor DNA in HCC and NET | NCT02973204 | Carcinoma, Hepa... Neuroendocrine ... | Sorafenib Radiofrequency ... Everolimus Lanreotide | 18 Years - | University of Aarhus | |
| Circulating Tumor Cells and Tumor DNA in HCC and NET | NCT02973204 | Carcinoma, Hepa... Neuroendocrine ... | Sorafenib Radiofrequency ... Everolimus Lanreotide | 18 Years - | University of Aarhus | |
| Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues | NCT02351128 | Carcinoma, Merk... | Lanreotide | 18 Years - | University Hospital, Grenoble |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
